Stakeholders in the European healthcare and pharmaceutical industry have published the Riga Roadmap, an action plan to make European Union health systems sustainable, equitable, and participatory. The Riga Roadmap is a result of the Universal Healthcare Conference, held in Riga, Latvia’, in late June, 28th, with the signatories being the European Generic and Biosimilar medicines Association, the European Federation of Pharmaceutical Industries and Associations, the European Patients’ Forum, and the European Public Health Alliance.
The signatories of the Riga Roadmap call on the Council of the European Union, as well as the European Council, European Parliament, European Commission, and the incoming Presidencies, for support in their efforts to implement the valuable objectives outlined in the Riga Roadmap. By providing a guide for action, the Riga Roadmap will support the successful implementation of four principles for European health: prevention, promotion, protection, and participation.
Objectives outlined in the Riga Roadmap include, among others:
• Identify appropriate and smarter ways of preventing ill health and avoidable costs to the system, in both health and economic terms, by promoting health throughout the life course, for instance: by implementing cost-effective preventative measures such as policies to tackle antimicrobial resistance, smoke-free policies; vaccination; and introducing fiscal measures to reduce consumption of unhealthy foods, alcohol and tobacco while making healthier foods more accessible and affordable;
• Create frameworks for meaningful patient involvement across the innovation chain in collaboration with the relevant parts of the EU Commission and stakeholders, from priority-setting and research design to regulatory processes, cost-benefit assessments, pricing and reimbursement, and the re-use/collection of patient data, whilst respecting the need for data protection;
• Include calls for systems and organizational innovation (e.g. integration of care, participatory medicine, patient involvement, culture change) under future EU programs in order for healthcare to better meet patients’ needs;
• Support the use of real-world evidence, to better understand opportunities to advance patient care while promoting efficient policies that balance support for innovation and the needed uptake for generic and biosimilar medicines to ensure access to medicines for all;
• Implement a regular EU Health literacy survey across all EU member states to collect comparative data, based on the validated EU Health Literacy Survey (HLS), and invest in health literacy interventions under various financial instruments (e.g. Health Programmes, Structural Funds).
The Riga Roadmap builds on the Vilnius Declaration of November 2013, which called for action in the three areas of: investment in health promotion and disease prevention; ensuring universal access to high quality people-centered health services; and ensuring health systems are evidence-based and grounded in common European values of solidarity, high quality, and equity of access while focusing on cost-effectiveness, sustainability, and good governance
Source: European Generic and medicines Association